Table III.
Study | The Same time period | Group | N | FIGO stage | Lymph node metastasis | Patients treated with adjuvant radiotherapy | Rate of positive margins | Removed lymph nodes | Team of operations | Type of surgery |
---|---|---|---|---|---|---|---|---|---|---|
Choi 2012 | Yes | LARVH | 89 | 3/11/73/2 (IA1/IA2/IB1/IIA) | 4 (4.5%) | 0 | 0 | 19.5 ±6.2 | 1 surgeon (DSB) | 3 II, 86 III |
ARH | 99 | 1/8/83/7 (IA1/IA2/IB1/IIA) | 7 (7.1%) | 0 | 0 | 20.4 ±7.7 | 1 surgeon (JHL) | 9 II, 90 III | ||
Gortchev 2012 | Yes | LARVH | 46 | 46 IB1 | 5 (10.9%)/ | NR | NR | 11.3 ±5.2 | 1 surgeon | Type III |
ARH | 175 | 175 IB1 | 42 (24.0%) | NR | NR | 15.9 ±7.7 | 2 surgeon | |||
Hou 2011 | Yes | LARVH | 33 | 4/10/15/4 (IA/IB/IIA/IIB) | 0 | NR | NR | 19.74 ±7.43 | The same group of surgeons | NR |
ARH | 30 | 2/10/14/4 (IA/IB/IIA/IIB) | 0 | NR | NR | 20.35 ±6.62 | ||||
Jackson 2004 | Yes | LARVH | 50 | 2/47/1 (IA2/IB1/IB2) | 1 (2%) | 7 (14%) | 5 (10%) | Median 15 | The same group of surgeons | NR |
ARH | 50 | 2/47/1 (IA2/IB1/IB2) | 1 (2%) | 2 (4%) | 1 (2%) | Median 16 | ||||
Malur 2001 | No | LARVH | 70 | 3/13/41/3/9/1/0 (IA1/IA2/IB/IIA/IIB/IIIA/IIIB) | NR | NR | NR | 27 (10–56)# | Senior registrars | Type II |
ARH | 70 | 1/1/51/5/11/0/1 (IA1/IA2/IB/IIA/IIB/IIIA/IIIB) | NR | 100% | NR | 10.7 (0–26) | ||||
Morgan 2007 | Yes | LARVH | 30 | 9/21/0/0 (IA/IB/IIA/IIB) | 0 | 1 (3.3%) | NR | 14.8 (3–37)# | The same group of surgeons | Type III |
ARH | 30 | 2/24/2/2 (IA/IB/IIA/IIB) | 5 (16.7%) | 2 (6.7%) | NR | 17.4 (6–36) | ||||
Naik 2010 | Yes | LARVH | 7 | 7 IB1 | 2 (28.57%) | 2 (28.57%) | 1 (14.29%) | 14 (12–19)# | The same group of surgeons | NR |
ARH | 6 | 6 IB1 | 1 (16.7%) | 1 (16.7%) | 0 (0.0%) | 12 (11–14) | ||||
Pahisa 2010 | No | LARVH | 67 | 3/61/3 (IA2/IB1/IIA) | 7 (10.4%) | 12 (17.9%) | 0 | 15.8 (10–33)# | J.P, S.M–R, or A.T. | NR |
ARH | 23 | 2/21/0 (IA2/IB1/IIA) | 3 (13.0%) | 5 (21.7%) | 0 | 12.4 (8–27) | ||||
Papacharalabous 2009 | Yes | LARVH | 14 | 14 (IA2–IB) | 1 (7.7%) | 1 (7.7%) | 0 | 22.4 ±10.6 | S.BM | NR |
ARH | 12 | 12 (IA2–IB) | 2 (16.7%) | 5 (41.67%) | 0 | 21.5 ±12.8 | A.T or S.BM | |||
Sharma 2006 | Yes | LARVH | 27 | 27/0 (IB1/IB2) | 0 (0.0%) | 0 (0.0%) | 0 | 23.5 (7–62)# | J.BM | NR |
ARH | 28 | 23/5 (IB1/IB2) | 2 (7.1%) | 2 (7.1%) | 0 | 27.6 (13–57) | J.BM and R.SA | |||
Steed 2004 | Yes | LARVH | 71 | 14/10/46/1 (IA1/IA2/IB1/IB2) | 5 (7.0%) | 16 (22.5%) | 1 (1.4%) | NR | One surgeon | NR |
ARH | 205 | 29/11/148/17 (IA1/IA2/IB1/IB2) | 19 (9.3%) | 43 (21.0%) | 6 (2.9%) | NR | Six surgeons | |||
Yu 2013 | Yes | LARVH | 40 | 12/17/9/2 (IA2/IB1/IB2/IIA) | 0 (0.0%) | 1 (2.5%) | 0 | 21.4 (18–28)# | The same group of surgeons | NR |
ARH | 40 | 6/15/13/6 (IA2/IB1/IB2/IIA) | 5 (12.5%) | 2 (5.0%) | 0 | 27.3 (19–32) | ||||
Zhang 2017 | Yes | LARVH | 35 | 4/13/10/6/2 (IA2/IB1/IB2/IIA/IIB) | NR | 20 (57.14%) | NR | 23.71 ±9.45 | The same 2 gynaecological oncology surgeons | Type III |
ARH | 42 | 2/20/8/8/4 (IA2/IB1/IB2/IIA/IIB) | NR | 24 (57.14%) | NR | 36.19 ±12.28 |
NR – not reported, FIGO – International Federation of Gynaecology and Obstetrics
mean (range).